These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 25525463)

  • 1. Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent.
    Pantziarka P; Bouche G; Meheus L; Sukhatme V; Sukhatme VP
    Ecancermedicalscience; 2014; 8():485. PubMed ID: 25525463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent.
    Pantziarka P; Bouche G; Meheus L; Sukhatme V; Sukhatme VP
    Ecancermedicalscience; 2014; 8():443. PubMed ID: 25075217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent.
    Pantziarka P; Sukhatme V; Bouche G; Meheus L; Sukhatme VP
    Ecancermedicalscience; 2015; 9():521. PubMed ID: 25932045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repurposing Drugs in Oncology (ReDO)-nitroglycerin as an anti-cancer agent.
    Sukhatme V; Bouche G; Meheus L; Sukhatme VP; Pantziarka P
    Ecancermedicalscience; 2015; 9():568. PubMed ID: 26435741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent.
    Pantziarka P; Sukhatme V; Bouche G; Meheus L; Sukhatme VP
    Ecancermedicalscience; 2016; 10():610. PubMed ID: 26823679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent.
    Pantziarka P; Bouche G; Sukhatme V; Meheus L; Rooman I; Sukhatme VP
    Ecancermedicalscience; 2016; 10():680. PubMed ID: 27899953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ReDO_DB: the repurposing drugs in oncology database.
    Pantziarka P; Verbaanderd C; Sukhatme V; Rica Capistrano I; Crispino S; Gyawali B; Rooman I; Van Nuffel AM; Meheus L; Sukhatme VP; Bouche G
    Ecancermedicalscience; 2018; 12():886. PubMed ID: 30679953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Repurposing Drugs in Oncology (ReDO) Project.
    Pantziarka P; Bouche G; Meheus L; Sukhatme V; Sukhatme VP; Vikas P
    Ecancermedicalscience; 2014; 8():442. PubMed ID: 25075216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents.
    Pantziarka P; Sukhatme V; Crispino S; Bouche G; Meheus L; Sukhatme VP
    Ecancermedicalscience; 2018; 12():824. PubMed ID: 29743944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents.
    Verbaanderd C; Maes H; Schaaf MB; Sukhatme VP; Pantziarka P; Sukhatme V; Agostinis P; Bouche G
    Ecancermedicalscience; 2017; 11():781. PubMed ID: 29225688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent.
    Van Nuffel AM; Sukhatme V; Pantziarka P; Meheus L; Sukhatme VP; Bouche G
    Ecancermedicalscience; 2015; 9():513. PubMed ID: 25729426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer.
    Deva S; Jameson M
    Cochrane Database Syst Rev; 2012 Aug; (8):CD007814. PubMed ID: 22895966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetic basis for H2-antagonist drug interactions: concepts and implications.
    Powell JR; Donn KH
    J Clin Gastroenterol; 1983; 5 Suppl 1():95-113. PubMed ID: 6140286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interactions of H2 antagonists and non-depolarizing muscle relaxants].
    Tryba M; Wruck G
    Anaesthesist; 1989 May; 38(5):251-4. PubMed ID: 2567580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cimetidine use and risk of prostate and breast cancer.
    Rossing MA; Scholes D; Cushing-Haugen KL; Voigt LF
    Cancer Epidemiol Biomarkers Prev; 2000 Mar; 9(3):319-23. PubMed ID: 10750671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of epidemiological studies on cancer in relation to the use of anti-ulcer drugs.
    La Vecchia C; Tavani A
    Eur J Cancer Prev; 2002 Apr; 11(2):117-23. PubMed ID: 11984128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and development of cimetidine as a histamine H2-receptor antagonist.
    Brimblecombe RW; Duncan WA; Durant GJ; Emmett JC; Ganellin CR; Leslie GB; Parsons ME
    Gastroenterology; 1978 Feb; 74(2 Pt 2):339-47. PubMed ID: 23336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An investigation into the effect of cimetidine pre-treatment on raft formation of an anti-reflux agent.
    Washington N; Wilson CG; Williams DL; Robertson C
    Aliment Pharmacol Ther; 1993 Oct; 7(5):553-9. PubMed ID: 8280824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repurposing cimetidine for cholangiocarcinoma: Antitumor effects
    Dana P; Vaeteewoottacharn K; Kariya R; Matsuda K; Wongkham S; Okada S
    Oncol Lett; 2017 Mar; 13(3):1432-1436. PubMed ID: 28454273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3H-cimetidine and the H2-receptor.
    Warrander SE; Norris DB; Rising RJ; Wood TP
    Life Sci; 1983 Sep; 33(12):1119-26. PubMed ID: 6888167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.